Discrete event simulation: the preferred technique for health economic evaluations?

OBJECTIVES To argue that discrete event simulation should be preferred to cohort Markov models for economic evaluations in health care. METHODS The basis for the modeling techniques is reviewed. For many health-care decisions, existing data are insufficient to fully inform them, necessitating the use of modeling to estimate the consequences that are relevant to decision-makers. These models must reflect what is known about the problem at a level of detail sufficient to inform the questions. Oversimplification will result in estimates that are not only inaccurate, but potentially misleading. RESULTS Markov cohort models, though currently popular, have so many limitations and inherent assumptions that they are inadequate to inform most health-care decisions. An event-based individual simulation offers an alternative much better suited to the problem. A properly designed discrete event simulation provides more accurate, relevant estimates without being computationally prohibitive. It does require more data and may be a challenge to convey transparently, but these are necessary trade-offs to provide meaningful and valid results. CONCLUSION In our opinion, discrete event simulation should be the preferred technique for health economic evaluations today.

[1]  O. Miettinen,et al.  Principles of nonexperimental assessment of excess risk, with special reference to adverse drug reactions. , 1989, Journal of clinical epidemiology.

[2]  Pierre L'Ecuyer,et al.  Efficiency improvement and variance reduction , 1994, Proceedings of Winter Simulation Conference.

[3]  J. Banks,et al.  Discrete-Event System Simulation , 1995 .

[4]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[5]  J Karnon,et al.  Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.

[6]  R. Lopert,et al.  Use of pharmacoeconomics in prescribing research. Part 5: modelling – beyond clinical trials , 2003, Journal of clinical pharmacy and therapeutics.

[7]  Uwe Siebert,et al.  When should decision-analytic modeling be used in the economic evaluation of health care? , 2003, The European Journal of Health Economics, formerly: HEPAC.

[8]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[9]  David M Eddy,et al.  Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. , 2006, PharmacoEconomics.

[10]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[11]  J Jaime Caro,et al.  Regarding probabilistic analysis and computationally expensive models: necessary and required? , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  Johan L Severens,et al.  Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  J. Caro,et al.  Pharmacoeconomic analyses using discrete event simulation , 2012, PharmacoEconomics.

[14]  James E. Stahl,et al.  Pharmacoeconomics 2008; 26 (2): 131-148 , 2012 .

[15]  Dr David M. Eddy Accuracy versus Transparency in Pharmacoeconomic Modelling , 2012, PharmacoEconomics.